{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:59:52Z","timestamp":1761919192995,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4847,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.exphem.2008.11.004","type":"journal-article","created":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T14:34:36Z","timestamp":1232548476000},"page":"357-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Proteasome proteolytic profile is linked to Bcr-Abl expression"],"prefix":"10.1016","volume":"37","author":[{"given":"Lisa J.","family":"Crawford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phlip","family":"Windrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Magill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junia V.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"McCallum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary F.","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huib","family":"Ovaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra E.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2008.11.004_bib1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.exphem.2008.11.004_bib2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.11.004_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.11.004_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.exphem.2008.11.004_bib5","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib6","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1006\/bbrc.1995.2878","article-title":"Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells","volume":"217","author":"Imajoh-Ohmi","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2008.11.004_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1042\/bj3170385","article-title":"Apoptosis induction resulting from proteasome inhibition","volume":"317","author":"Shinohara","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2008.11.004_bib8","first-page":"2798","article-title":"Eponemycin exerts it antitumour effect through inhibition of proteasome function","volume":"59","author":"Meng","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib9","first-page":"4342","article-title":"Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor","volume":"58","author":"Orlowski","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/1535-7163.59.3.1","article-title":"The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts","volume":"3","author":"Nawrocki","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2008.11.004_bib11","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib12","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cncr.22097","article-title":"Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"107","author":"Faderl","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2008.11.004_bib13","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib14","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/cncr.22700","article-title":"Efficacy and safety of Bortezomib in patients with plasma cell leukemia","volume":"109","author":"Musto","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2008.11.004_bib15","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.leukres.2007.11.010","article-title":"Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?","volume":"32","author":"Katodritou","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib16","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1158\/1078-0432.CCR-07-4626","article-title":"Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia","volume":"14","author":"Attar","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib17","doi-asserted-by":"crossref","first-page":"16220","DOI":"10.1073\/pnas.252462599","article-title":"Preferential induction of apoptosis for primary human leukemic stem cells","volume":"99","author":"Guzman","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2008.11.004_bib18","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","article-title":"The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571","volume":"102","author":"Yu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.004_bib19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood-2003-12-4121","article-title":"Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr\/Abl-dependent and -independent mechanisms","volume":"104","author":"Dai","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.004_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2005-06-2302","article-title":"The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism","volume":"107","author":"Dasmahapatra","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.004_bib21","first-page":"1428","article-title":"Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma","volume":"89","author":"Magill","year":"2004","journal-title":"Hematalogica"},{"key":"10.1016\/j.exphem.2008.11.004_bib22","doi-asserted-by":"crossref","first-page":"25200","DOI":"10.1074\/jbc.272.40.25200","article-title":"The active sites of the eukaryotic 20S proteasome and their involvement in subunit precursor processing","volume":"272","author":"Heinemeyer","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.11.004_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000468687","article-title":"Catalytic components of the bovine pituitary multicatalytic proteinase complex (proteasome)","volume":"47","author":"Cardozo","year":"1993","journal-title":"Enzyme Protein"},{"key":"10.1016\/j.exphem.2008.11.004_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)80341-X","article-title":"Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown","volume":"4","author":"Kisselev","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2008.11.004_bib25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1006\/jmbi.1999.2995","article-title":"Proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function","volume":"291","author":"Jager","year":"1999","journal-title":"J Mol Biol"},{"key":"10.1016\/j.exphem.2008.11.004_bib26","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1074\/jbc.M509043200","article-title":"Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate","volume":"281","author":"Kisselev","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.11.004_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sj.leu.2404414","article-title":"Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells","volume":"21","author":"Kraus","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2008.11.004_bib28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/cncr.23224","article-title":"Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits","volume":"112","author":"Busse","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2008.11.004_bib29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.onc.1201969","article-title":"P210 bcr-abl expression in a primitive haematopoietic cell line models the development of chronic myeloid leukaemia","volume":"17","author":"Pierce","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2008.11.004_bib30","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.004_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0960-894X(98)00030-4","article-title":"Inhibitors of the chymotrypsin-like activity of the proteasome based on di- and tri-peptidyl \u03b1-keto aldehydes (glyoxals)","volume":"8","author":"Lynas","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.exphem.2008.11.004_bib32","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.273.5.2926","article-title":"An induced proximity model for caspase-8 activation","volume":"273","author":"Muzio","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.11.004_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth759","article-title":"Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib","volume":"2","author":"Berkers","year":"2005","journal-title":"Nat Methods"},{"key":"10.1016\/j.exphem.2008.11.004_bib34","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","article-title":"Specific inhibition of bcr-abl gene expression by small interfering RNA","volume":"101","author":"Scherr","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.004_bib35","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe against cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2008.11.004_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.exphem.2008.11.004_bib37","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in leukaemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2008.11.004_bib38","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-04-1357","article-title":"BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells","volume":"65","author":"Andreu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib39","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.leu.2401812","article-title":"Protease inhibitor induced apoptosis: Accumulation of wt p53, p21 WAF1\/CIP1 and induction of apoptosis are independent markers of proteasome inhibition","volume":"14","author":"An","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2008.11.004_bib40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hon.813","article-title":"Therapeutic targets in chronic myeloid leukaemia","volume":"25","author":"Heaney","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.exphem.2008.11.004_bib41","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1101\/gad.12.10.1415","article-title":"Oncogenic abl and src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a ras-independent pathway","volume":"12","author":"Dai","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.exphem.2008.11.004_bib42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0301-472X(00)00673-1","article-title":"CIS1, a cytokine-inducible SH2 protein, suppresses BCR\/ABL-mediated transformation","volume":"29","author":"Tauchi","year":"2001","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2008.11.004_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as a paradigm of targeted therapies","volume":"91","author":"Druker","year":"2004","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib44","first-page":"2118","article-title":"Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and-resistant Bcr\/Abl+ human myeloid leukemia cells","volume":"63","author":"Yu","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib45","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.004_bib46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V99.2.664","article-title":"Effects of the Bcr\/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro","volume":"99","author":"Mow","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.11.004_bib47","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib48","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.exphem.2008.11.004_bib49","first-page":"853","article-title":"The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr-Abl-positive cell lines sensitive and resistant to imatinib mesylate","volume":"88","author":"Gatto","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2008.11.004_bib50","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1158\/0008-5472.CAN-06-0605","article-title":"Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341 and MG-132","volume":"66","author":"Crawford","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.11.004_bib51","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.11.004_bib52","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bjc.6603406","article-title":"A novel proteasome inhibitor NPI-0052 as an anticancer therapy","volume":"95","author":"Chauhan","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2008.11.004_bib53","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08005225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08005225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:26:51Z","timestamp":1759566411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X08005225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0301472X08005225"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2008.11.004","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteasome proteolytic profile is linked to Bcr-Abl expression","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2008.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}